Lincoln Pharmaceuticals Share Price Falls 2.37% After Weak Q2 FY26 Financial Result

Ahmedabad, November 13: Lincoln Pharmaceuticals share price is witnessing negative investor demand today after it reported a weak financial performance for the quarter ending September 30, 2025. As of 2:17 PM, share price was down by 2.37%, or 12.55 points, and was trading at ₹517.25. Until now, the shares have traded within a range of ₹540 and ₹509.45. The traded volume for Lincoln Pharmaceuticals stock stood at 1.01 lakh shares, with the company’s market cap at ₹1,061 crore. The shares have their 52-week high at ₹979.50 and their 52-week low at ₹499.

Lincoln Pharmaceuticals Ltd (NSE: LINCOLN, BSE: 531663) is an Indian multinational pharmaceutical company that is engaged in the business of manufacturing, marketing, and distributing pharmaceutical products. The company has a diversified portfolio with over 600 formulations across 15 therapeutic areas, including anti-infectives, respiratory, gynaecology, and cardio & CNS. The company was established in 1979, and is headquartered in Ahmedabad, Gujarat.

Shares Fall After Weak Q2 FY26 Financial Results

For Q2 FY26, the company reported revenue from operations of ₹16,336.39 lakh, compared to ₹16,121.35 lakh in Q2 FY25. Including other income of ₹723.21 lakh, total income stood at ₹17,059.60 lakh, almost flat compared to ₹17,119.11 lakh last year. Total expenses came in at ₹14,178.52 lakh, lower than the ₹13,640.79 lakh reported in Q2 FY25. The company posted a profit before tax (PBT) of ₹2,881.08 lakh, lower than ₹3,478.32 lakh a year ago. After accounting for tax expenses of ₹861.90 lakh (current) and a deferred tax credit of ₹12.45 lakh, net profit stood at ₹1,998.40 lakh, lower than ₹2,633.03 lakh in Q2 FY25. For the half year ended 30 September 2025 (H1 FY26), total income was ₹33,993.44 lakh, higher than ₹32,888.21 lakh in H1 FY25. Net profit for the period stood at ₹4,765.92 lakh, slightly lower than ₹5,000.20 lakh in the same period last year.

Investor Takeaway for Lincoln Pharmaceuticals

Lincoln Pharmaceuticals reported a weak financial result for Q2 FY26, with profit before and after tax falling. Although its revenue increased, the rise was modest. The weak financials have lowered investor demand, leading to a fall in the share price.

REF: https://nsearchives.nseindia.com/corporate/LINCOLN_13112025122810_outcome13112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations